Oorsprong van het eerstegraads netwerk van Kazuo Suzuki
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Generic | 8 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Kazuo Suzuki via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| SUMITOMO PHARMA CO., LTD. | Pharmaceuticals: Major | Director/Board Member | |
| SUMITOMO CHEMICAL CO., LTD. | Chemicals: Specialty | Corporate Officer/Principal | |
| TOWA PHARMACEUTICAL CO., LTD. | Pharmaceuticals: Major | Director/Board Member | |
| MORISHITA JINTAN CO., LTD. | Pharmaceuticals: Other | President | |
| TAKARA BIO INC. | Medical Specialties | Director/Board Member | |
| SOLASIA PHARMA K.K. | Pharmaceuticals: Major | Director/Board Member | |
| AnGes Euro Ltd. | Chief Executive Officer Director/Board Member | ||
AnGes USA, Inc.
 AnGes USA, Inc. Pharmaceuticals: MajorHealth Technology Part of AnGes, Inc., AnGes USA, Inc. develops and manufactures medicines. The company is based in Gaithersburg, MD. Ei Yamada has been the CEO of the company since 2014. | Pharmaceuticals: Major | Chief Executive Officer | |
| FUNPEP COMPANY LIMITED | Biotechnology | Director/Board Member | |
MyBiotics Pharma Ltd.
 MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | Biotechnology | Director/Board Member | |
Oriciro Genomics, Inc.
 Oriciro Genomics, Inc. BiotechnologyHealth Technology Oriciro Genomics, Inc. develops DNA based assembly and amplification technology solutions. The company was founded in December 2018 and is headquartered in Tokyo, Japan. | Biotechnology | Chief Executive Officer | |
Emendo Biotherapeutics, Inc.
 Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | Biotechnology | Director/Board Member | |
| Point Market KK | Director/Board Member | ||
| KIDSWELL BIO CORPORATION | Biotechnology | Director/Board Member |
Statistieken
Internationaal
| Japan | 11 |
| Verenigde Staten | 3 |
| Verenigd Koninkrijk | 2 |
| Israël | 2 |
Sectoraal
| Health Technology | 12 |
| Process Industries | 2 |
Operationeel
| Director/Board Member | 17 |
| Independent Dir/Board Member | 7 |
| Chief Executive Officer | 3 |
| Corporate Officer/Principal | 3 |
| Comptroller/Controller/Auditor | 3 |
Sterkste connecties
| Insiders | |
|---|---|
| Ei Yamada | 6 |
| Norikazu Eiki | 5 |
| Makoto Hara | 3 |
| Junichi Komamura | 3 |
| Seiji Hirasaki | 3 |
| Tetsuji Yoneo | 1 |
| Jun Sakurai | 1 |
| Hajime Watanabe | 1 |
- Beurs
- Insiders
- Kazuo Suzuki
- Bedrijfsconnecties
